Comparison of O-Linked Carbohydrate Chains in MUC-1 Mucin from Normal Breast Epithelial Cell Lines and Breast Carcinoma Cell Lines:

MUC-1 mucin is considered to be aberrantly glycosylated in breast, ovary, and other carcinomas in comparison with mucin from corresponding normal tissues. In order to clarify these differences in glycosylation, we have compared the O-linked carbohydrate chains from MUC-1 immunoprecipitated from [3H]GlcN-labeled breast epithelial cell lines (MMSV1-1, MTSV1-7, and HB-2) derived from cells cultured from human milk, with three breast cancer cell lines (MCF-7, BT-20, and T47D). Analysis by high pH anion chromatography showed that the normal cell lines had a higher ratio of GlcN/GalN and more complex oligosaccharide profiles than the cancer cell lines. Structural analyses were carried out on the oligosaccharides from MTSV1-7 and T47D MUC-1, and the following structures were proposed. MUC-1 from T47D had rather a simple glycosylation pattern, with NeuAcα2-3Galβ1-3GalNAc-ol, Galβ1-3GalNAc-ol, and GalNAc-ol predominating; in contrast, MUC-1 from MTSV1-7 had more complex structures, including a number of disialo, core 2 species, i.e. NeuAcα2-3Galβ1-4GlcNAcβ1-6[NeuAcα2-3Galβ1-3]GalNAc-ol and NeuAcα2-3Galβ1-4GlcNAcβ1-6[NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-3]GalNAc-ol. Double-labeling experiments with [3H]GlcN and 14C-aminoacids and analysis of GalNAc or GalNAc-ol:protein ratios in MUC-1 showed that there was also a significant difference in the degree of glycosylation of the mucin between the two cell types. We conclude that MUC-1 from breast cancer cell lines has simpler, and fewer, carbohydrate chains than MUC-1 from normal breast epithelial cells, and that these differences, combined or separately, explain the differential tumor specificity of some MUC-1 antibodies and T cells.

[1]  M. Radu,et al.  Establishment and characterization of a cell line of human breast carcinoma origin. , 1979, European journal of cancer.

[2]  F. Borek Antigen and antibody molecular engineering in breast cancer diagnosis and treatment , 1995 .

[3]  N. Karlsson,et al.  Analysis of monosaccharide composition of mucin oligosaccharide alditols by high-performance anion-exchange chromatography. , 1995, Analytical biochemistry.

[4]  K. Lloyd,et al.  Mild alkaline borohydride treatment of glycoproteins-a method for liberating both N- and O-linked carbohydrate chains. , 1982, Analytical biochemistry.

[5]  M. Fukuda,et al.  T-lymphocytic leukemia expresses complex, branched O-linked oligosaccharides on a major sialoglycoprotein, leukosialin. , 1991, Blood.

[6]  J. Taylor‐Papadimitriou,et al.  Branching morphogenesis of human mammary epithelial cells in collagen gels. , 1994, Journal of cell science.

[7]  J. Taylor‐Papadimitriou,et al.  The Polymorphic Epithelial Mucin as a Target for Immunotherapy a , 1993, Annals of the New York Academy of Sciences.

[8]  G J Strous,et al.  Mucin-type glycoproteins. , 1992, Critical reviews in biochemistry and molecular biology.

[9]  K. Jerome,et al.  Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. , 1993, Journal of immunology.

[10]  I. Brockhausen,et al.  Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. , 1995, European journal of biochemistry.

[11]  S. Gendler,et al.  Epithelial mucin genes. , 1995, Annual review of physiology.

[12]  J. Taylor‐Papadimitriou Report on the first international workshop on carcinoma‐associated mucins , 1991, International journal of cancer.

[13]  B. Siddiki,et al.  Association of Sialyl-Lewisa and Sialyl-Lewisx with MUC-1 Apomucin in a Pancreatic Cancer Cell Line , 1995 .

[14]  J. Wieruszeski,et al.  Oligosaccharide structures of mucins secreted by the human colonic cancer cell line CL.16E. , 1992, The Journal of biological chemistry.

[15]  J. Taylor‐Papadimitriou,et al.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. , 1987, Cancer research.

[16]  J. Taylor‐Papadimitriou,et al.  Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout mammals. , 1992, Biochemical and biophysical research communications.

[17]  N. Peat,et al.  Structure and biology of a carcinoma-associated mucin, MUC1. , 1991, The American review of respiratory disease.

[18]  M. Ligtenberg,et al.  Complexity of MAM-6, an epithelial sialomucin associated with carcinomas. , 1989, Cancer research.

[19]  D. M. Carlson,et al.  Alkaline borohydride degradation of blood group H substance. , 1971, Archives of biochemistry and biophysics.

[20]  W. Bodmer,et al.  Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.

[21]  J. Peter-Katalinic,et al.  Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units. , 1989, The Journal of biological chemistry.

[22]  E Y LASFARGUES,et al.  Cultivation of human breast carcinomas. , 1958, Journal of the National Cancer Institute.

[23]  E. Kabat,et al.  [Immunochemical studies on blood groups. 38. Structures and activities of oligosaccharides produced by alkaline degradation of blood-group Lewis-a substance. Proposed structure of the carbohydrate chains of human blood-group A, B, H, Le-a, and Le-b substances]. , 1968, Biochemistry.

[24]  R. Townsend,et al.  Monosaccharide analysis of glycoconjugates by anion exchange chromatography with pulsed amperometric detection. , 1988, Analytical biochemistry.

[25]  V. Apostolopoulos,et al.  Peptide epitopes in breast cancer mucins. , 1994, Advances in experimental medicine and biology.

[26]  J. Bartek,et al.  Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Bártková,et al.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas , 1989, International journal of cancer.

[28]  F. D'Agostini,et al.  Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. , 1996, European journal of cancer.

[29]  A. Kobata,et al.  Analysis of oligosaccharides by gel filtration. , 1982, Methods in enzymology.

[30]  J. Sheehan,et al.  Mucous glycoproteins: a gel of a problem. , 1985, Essays in biochemistry.

[31]  N. Peat,et al.  Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. , 1990, Biochemical and biophysical research communications.

[32]  J. Peter-Katalinic,et al.  MUC1 Glycoforms in Breast Cancer , 1996 .

[33]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.